Top

30-01-2025 | Alzheimer's Disease | Review

Uncovering the intricacies of IGF-1 in Alzheimer’s disease: new insights from regulation to therapeutic targeting

Authors: Navpreet Kaur, Khadga Raj Aran

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-β plaques and tau tangles, leading to cognitive decline and dementia. Insulin-like Growth Factor-1 (IGF-1) is similar in structure to insulin and is crucial for cell growth, differentiation, and regulating oxidative stress, synaptic plasticity, and mitochondrial function. IGF-1 exerts its physiological effects by binding to the IGF-1 receptor (IGF-1R) and activating PI3K/Akt pathway. In addition to the physiological activities in the brain, numerous studies point to a potential protective role of the IGF-1 pathway in the pathogenesis of neurodegenerative diseases, such as AD. Interestingly, patients with AD often exhibit altered insulin and IGF-1 levels, along with an inadequate insulin response. Dysregulation of IGF-1 signaling contributes to hyperphosphorylation of tau, NFT accumulation, increased β- and γ-secretase activity, elevated Aβ production, and impaired Aβ clearance, highlighting the need to explore the role of this signaling for potential therapeutic targets of AD. This review explores the role of IGF signaling in AD pathology, highlighting IGF-1 as a promising therapeutic target due to its significant involvement in disease mechanisms. Modulating IGF-1 activity could help mitigate neurodegeneration and preserve cognitive function in AD. A comprehensive understanding of the mechanisms underlying IGF-1 dysregulation is crucial for developing targeted therapeutic strategies to address the complex and multifaceted nature of AD.

Åberg ND, Brywe KG, Isgaard J (2006) Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration, and functional plasticity in the adult brain. Sci World J 6:53–80. https://doi.org/10.1100/tsw.2006.22CrossRef

Adlerz L, Holback S, Multhaup G, Iverfeldt K (2007) IGF-1-induced processing of the amyloid precursor protein family is mediated by different signaling pathways. J Biol Chem 282(14):10203–10209. https://doi.org/10.1074/jbc.M611183200CrossRefPubMed

Aguado-Llera D, Canelles S, Frago LM, Chowen JA, Argente J, Arilla E, Barrios V (2018) The protective effects of IGF-I against β-amyloid-related downregulation of hippocampal somatostatinergic system involve activation of Akt and protein kinase a. Neuroscience 374:104–118. https://doi.org/10.1016/j.neuroscience.2018.01.041CrossRefPubMed

Ano Y, Ohya R, Takaichi Y, Washinuma T, Uchida K, Takashima A, Nakayama H (2020) Β-lactolin, a whey-derived lacto-tetrapeptide, prevents Alzheimer’s disease pathologies and cognitive decline. J Alzheimer’s Dis 73(4):1331–1342. https://doi.org/10.3233/JAD-190997CrossRef

Arjunan A, Sah DK, Woo M, Song J (2023) Identification of the molecular mechanism of insulin-like growth factor-1 (IGF-1): a promising therapeutic target for neurodegenerative diseases associated with metabolic syndrome. Cell Biosci 13(1):16. https://doi.org/10.1186/s13578-023-00966-zCrossRefPubMedCentralPubMed

Bagyinszky E, Van Giau V, Shim K, Suk K, An SS, Kim S (2017) Role of inflammatory molecules in the Alzheimer’s disease progression and diagnosis. J Neurol Sci 376:242–254. https://doi.org/10.1016/j.jns.2017.03.031CrossRefPubMed

Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV (2012) Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol 69(11):1420–1429. https://doi.org/10.1001/archneurol.2012.1970CrossRefPubMedCentralPubMed

Barbier P, Zejneli O, Martinho M, Lasorsa A, Belle V, Smet-Nocca C, Tsvetkov PO, Devred F, Landrieu I (2019) Role of tau as a microtubule-associated protein: structural and functional aspects. Front Aging Neurosci 11:204. https://doi.org/10.3389/fnagi.2019.00204CrossRefPubMedCentralPubMed

Bhalla S, Mehan S, Khan A, Rehman MU (2022) Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions. Neurosci Biobehav Rev 142:104896. https://doi.org/10.1016/j.neubiorev.2022.104896CrossRefPubMed

Birkenkamp KU, Coffer PJ (2003) Regulation of cell survival and proliferation by the FOXO (Forkhead box, class O) subfamily of Forkhead transcription factors. Biochem Soc Trans 31(1):292–297. https://doi.org/10.1042/bst0310292CrossRefPubMed

Blázquez E, Velázquez E, Hurtado-Carneiro V, Ruiz-Albusac JM (2014) Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer’s disease. Front Endocrinol 5:161. https://doi.org/10.3389/fendo.2014.00161CrossRef

Bolos M, Fernandez S, Torres-Aleman I (2010) Oral administration of a GSK3 inhibitor increases brain insulin-like growth factor I levels. J Biol Chem 285(23):17693–17700. https://doi.org/10.1074/jbc.M109.096594CrossRefPubMedCentralPubMed

Bonfili L, Cecarini V, Gogoi O, Berardi S, Scarpona S, Angeletti M, Rossi G, Eleuteri AM (2020) Gut microbiota manipulation through probiotics oral administration restores glucose homeostasis in a mouse model of Alzheimer’s disease. Neurobiol Aging 87:35–43. https://doi.org/10.1016/j.neurobiolaging.2019.11.004CrossRefPubMed

Boura-Halfon S, Zick Y (2009) Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab 296(4):581–591. https://doi.org/10.1152/ajpendo.90437.2008CrossRef

Cao Z, Min J, Tan Q, Si K, Yang H, Xu C (2023) Circulating insulin-like growth factor-1 and brain health: Evidence from 369,711 participants in the UK Biobank. Alzheimer’s Res Ther 15(1):140. https://doi.org/10.1186/s13195-023-01288-5CrossRef

Carro E, Trejo JL, Gerber A, Loetscher H, Torrado J, Metzger F, Torres-Aleman I (2006) Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiol Aging 27(9):1250–1257. https://doi.org/10.1016/j.neurobiolaging.2005.06.015CrossRefPubMed

Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I (2002) Serum insulin-like growth factor I regulates brain amyloid-β levels. Nat Med 8(12):1390–1397. https://doi.org/10.1038/nm1202-793CrossRefPubMed

Chávez V, Mohri-Shiomi A, Maadani A, Vega LA, Garsin DA (2007) Oxidative stress enzymes are required for DAF-16-mediated immunity due to generation of reactive oxygen species by Caenorhabditis elegans. Genetics 176(3):1567–1577. https://doi.org/10.1534/genetics.107.072587CrossRefPubMedCentralPubMed

Chen F, Lu K, Bai N, Hao Y, Wang H, Zhao X, Yue F (2024) Oral administration of ellagic acid mitigates perioperative neurocognitive disorders, hippocampal oxidative stress, and neuroinflammation in aged mice by restoring IGF-1 signaling. Sci Rep 14(1):2509. https://doi.org/10.1038/s41598-024-53127-8CrossRefPubMedCentralPubMed

Chen S, Wang T, Yao J, Brinton RD (2020) Allopregnanolone promotes neuronal and oligodendrocyte differentiation in vitro and in vivo: therapeutic implication for Alzheimer’s disease. Neurotherapeutics 17(4):1813–1824. https://doi.org/10.1007/s13311-020-00874-xCrossRefPubMedCentralPubMed

Cheng CM, Tseng V, Wang J, Wang D, Matyakhina L, Bondy CA (2005) Tau is hyperphosphorylated in the insulin-like growth factor-I null brain. Endocrinology 146(12):5086–5091. https://doi.org/10.1210/en.2005-0063CrossRefPubMed

Chu S, Gu J, Feng L, Liu J, Zhang M, Jia X, Liu M, Yao D (2014) Ginsenoside Rg5 improves cognitive dysfunction and beta-amyloid deposition in STZ-induced memory impaired rats via attenuating neuroinflammatory responses. Int Immunopharmacol 19(2):317–326. https://doi.org/10.1016/j.intimp.2014.01.018CrossRefPubMed

Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A (2006) Opposing activities protect against age-onset proteotoxicity. Science 313(5793):1604–1610. https://doi.org/10.1126/science.1124646CrossRefPubMed

Cortés N, Andrade V, Guzmán-Martínez L, Estrella M, Maccioni RB (2018) Neuroimmune tau mechanisms: their role in the progression of neuronal degeneration. Int J Mol Sci 19(4):956. https://doi.org/10.3390/ijms19040956CrossRefPubMedCentralPubMed

Costales J, Kolevzon A (2016) The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders. Neurosci Biobehav Rev 63:207–222. https://doi.org/10.1016/j.neubiorev.2016.01.001CrossRefPubMedCentralPubMed

Costantini C, Scrable H, Puglielli L (2006) An aging pathway controls the TrkA to p75NTR receptor switch and amyloid β-peptide generation. EMBO J 25(9):1997–2006. https://doi.org/10.1038/sj.emboj.7601062CrossRefPubMedCentralPubMed

D Skaper S, Facci L, Zusso M, Giusti P (2017) Synaptic plasticity, dementia and Alzheimer disease. CNS Neurol Disord Drug Targets 16(3):220-33

Das TK, Chakrabarti SK, Zulkipli IN, Abdul Hamid MR (2019) Curcumin ameliorates the impaired insulin signaling involved in the pathogenesis of Alzheimer’s disease in rats. J Alzheimer’s Dis Rep 3(1):59–70. https://doi.org/10.3233/ADR-180091CrossRef

De la Monte SM, Chen GJ, Rivera E, Wands JR (2003) Neuronal thread protein regulation and interaction with microtubule-associated proteins in SH-Sy5y neuronal cells. Cell Mol Life Sci 60:2679–2691. https://doi.org/10.1007/s00018-003-3305-3CrossRefPubMedCentralPubMed

de la Vega AG, Buno W, Pons S, Garcia-Calderat MS, Garcia-Galloway E, Torres-Aleman I (2001) Insulin-like growth factor I potentiates kainate receptors through a phosphatidylinositol 3-kinase dependent pathway. NeuroReport 12(6):1293–1296. https://doi.org/10.1097/00001756-200105080-00047CrossRef

Eckman EA, Eckman CB (2005) Aβ-degrading enzymes: modulators of Alzheimer’s disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 33(5):1101–1105. https://doi.org/10.1042/BST0331101CrossRefPubMed

Fadl NN, Ahmed HH, Booles HF, Sayed AH (2013) Serrapeptase and nattokinase intervention for relieving Alzheimer’s disease pathophysiology in rat model. Hum Exp Toxicol 32(7):721–735. https://doi.org/10.1177/0960327112467040CrossRefPubMed

Fernandez AM, Jimenez S, Mecha M, Davila D, Guaza C, Vitorica J, Torres-Aleman I (2012) Regulation of the phosphatase calcineurin by insulin-like growth factor I unveils a key role of astrocytes in Alzheimer’s pathology. Mol Psychiatry 17(7):705–718. https://doi.org/10.1038/mp.2011.128CrossRefPubMed

Fernandez M, Sanchez-Franco F, Palacios N, Sanchez I, Fernandez C, Cacicedo L (2004) IGF-I inhibits apoptosis through the activation of the phosphatidylinositol 3-kinase/Akt pathway in pituitary cells. J Mol Endocrinol 33(1):155–164CrossRefPubMed

Friedman SD, Baker LD, Borson S, Jensen JE, Barsness SM, Craft S, Merriam GR, Otto RK, Novotny EJ, Vitiello MV (2013) Growth Hormone-Releasing Hormone effects on brain γ-Aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurol 70(7):883–890. https://doi.org/10.1001/jamaneurol.2013.1425CrossRefPubMedCentralPubMed

Garcia-Segura LM, Rodriguez JR, Torres-Aleman I (1997) Localization of the insulin-like growth factor I receptor in the cerebellum and hypothalamus of adult rats: an electron microscopic study. J Neurocytol 26(7):479–490. https://doi.org/10.1023/A:1018581407804CrossRefPubMed

Go J, Chang DH, Ryu YK, Park HY, Lee IB, Noh JR, Hwang DY, Kim BC, Kim KS, Lee CH (2021) Human gut microbiota Agathobaculum butyriciproducens improves cognitive impairment in LPS-induced and APP/PS1 mouse models of Alzheimer’s disease. Nutr Res 86:96–108. https://doi.org/10.1016/j.nutres.2020.12.010CrossRefPubMed

Gouras GK, Olsson TT, Hansson O (2015) β-Amyloid peptides and amyloid plaques in Alzheimer’s disease. Neurotherapeutics 12(1):3–11. https://doi.org/10.1007/s13311-014-0313-yCrossRefPubMed

Han B, Tong J, Zhu MJ, Ma C, Du M (2008) Insulin-like growth factor-1 (IGF-1) and leucine activate pig myogenic satellite cells through mammalian target of rapamycin (mTOR) pathway. Mol Reprod Dev 75(5):810–817. https://doi.org/10.1002/mrd.20832CrossRefPubMed

Hemming ML, Selkoe DJ, Farris W (2007) Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid β-protein metabolism in mouse models of Alzheimer disease. Neurobiol Dis 26(1):273–281. https://doi.org/10.1016/j.nbd.2007.01.004CrossRefPubMedCentralPubMed

Herrera ML, Champarini LG, Oliveros AL, Bellini MJ, Hereñú CB (2024) Potentialities of IGF-1 for regulating oxidative stress in neuroinflammation and neurodegeneration: theoretical review. Explor neuroprot ther 4(6):442–58. https://doi.org/10.37349/ent.2024.00093

Herrero-Labrador R, Trueba-Saiz A, Martinez-Rachadell L, Fernandez de Sevilla ME, Zegarra-Valdivia JA, Pignatelli J, Diaz-Pacheco S, Fernandez AM, Torres Aleman I (2020) Circulating insulin-like growth factor I is involved in the effect of high fat diet on peripheral amyloid β clearance. Int J Mol Sci 21(24):9675. https://doi.org/10.3390/ijms21249675CrossRefPubMedCentralPubMed

Hong M, Lee VM (1997) Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 272(31):19547–19553. https://doi.org/10.1074/jbc.272.31.19547CrossRefPubMed

Huang SM, Mouri A, Kokubo H, Nakajima R, Suemoto T, Higuchi M, Staufenbiel M, Noda Y, Yamaguchi H, Nabeshima T, Saido TC (2006) Neprilysin-sensitive synapse-associated amyloid-β peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem 281(26):17941–17951. https://doi.org/10.1074/jbc.M601372200CrossRefPubMed

Improta-Caria AC, Nonaka CK, Cavalcante BR, De Sousa RA, Aras Junior R, Souza BS (2020) Modulation of microRNAs as a potential molecular mechanism involved in the beneficial actions of physical exercise in Alzheimer disease. Int J Mol Sci 21(14):4977. https://doi.org/10.3390/ijms21144977CrossRefPubMedCentralPubMed

Jacobsen KT, Adlerz L, Multhaup G, Iverfeldt K (2010) Insulin-like growth factor-1 (IGF-1)-induced processing of amyloid-β precursor protein (APP) and APP-like protein 2 is mediated by different metalloproteinases. J Biol Chem 285(14):10223–10231. https://doi.org/10.1074/jbc.M109.038224CrossRefPubMedCentralPubMed

Jiang G, Wang W, Cao Q, Gu J, Mi X, Wang K, Chen G, Wang X (2015) Insulin growth factor-1 (IGF-1) enhances hippocampal excitatory and seizure activity through IGF-1 receptor-mediated mechanisms in the epileptic brain. Clin Sci 129(12):1047–1060. https://doi.org/10.1042/CS20150312CrossRef

Jimenez S, Torres M, Vizuete M, Sanchez-Varo R, Sanchez-Mejias E, Trujillo-Estrada L, Carmona-Cuenca I, Caballero C, Ruano D, Gutierrez A, Vitorica J (2011) Age-dependent accumulation of soluble amyloid β (Aβ) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-α (sAPPα) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3β pathway in Alzheimer mouse model. J Biol Chem 286(21):18414–18425. https://doi.org/10.1074/jbc.M110.209718CrossRefPubMedCentralPubMed

Jin N, Yin X, Yu D, Cao M, Gong CX, Iqbal K, Ding F, Gu X, Liu F (2015) Truncation and activation of GSK-3β by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer’s disease. Sci Rep 5(1):8187. https://doi.org/10.1038/srep08187CrossRefPubMedCentralPubMed

Joung YH, Lee MY, Lim EJ, Kim MS, Hwang TS, Kim SY, Ye SK, Lee JD, Park T, Woo YS, Chung IM (2007) Hypoxia activates the IGF-1 expression through STAT5b in human HepG2 cells. Biochem Biophys Res Commun 358(3):733–738. https://doi.org/10.1016/j.bbrc.2007.04.201CrossRefPubMed

Józefiak A, Larska M, Pomorska-Mól M, Ruszkowski JJ (2021) The IGF-1 signaling pathway in viral infections. Viruses 13(8):1488. https://doi.org/10.3390/v13081488bCrossRefPubMedCentralPubMed

Kasprzak A, Adamek A (2012) The insulin-like growth factor (IGF) signaling axis and hepatitis C virus-associated carcinogenesis. Int J Oncol 41(6):1919–1931. https://doi.org/10.3892/ijo.2012.1666CrossRefPubMed

Lecomte MJ, Bertolus C, Ramanantsoa N, Saurini F, Callebert J, Senamaud-Beaufort C, Ringot M, Bourgeois T, Matrot B, Collet C, Nardelli J (2018) Acetylcholine modulates the hormones of the growth hormone/insulinlike growth factor-1 axis during development in mice. Endocrinology 159(4):1844–1859. https://doi.org/10.1210/en.2017-03175CrossRefPubMed

LeRoith D, Holly JMP, Forbes BE (2021) Insulin-like growth factors: ligands, binding proteins, and receptors. Mol Metab 52:101245. https://doi.org/10.1016/j.molmet.2021.101245CrossRefPubMedCentralPubMed

Liu J, Speder P, Brand AH (2014) Control of brain development and homeostasis by local and systemic insulin signalling. Diabetes Obes Metab 16(S1):16–20. https://doi.org/10.1111/dom.12337CrossRefPubMed

Liu P, Cui L, Liu B, Liu W, Hayashi T, Mizuno K, Hattori S, Ushiki-Kaku Y, Onodera S, Ikejima T (2020) Silibinin ameliorates STZ-induced impairment of memory and learning by up-regulating insulin signaling pathway and attenuating apoptosis. Physiol Behav 213:112689. https://doi.org/10.1016/j.physbeh.2019.112689CrossRefPubMed

Liu P, Zou L, Jiao Q, Chi T, Ji X, Qi Y, Xu Q, Wang L (2013) Xanthoceraside attenuates learning and memory deficits via improving insulin signaling in STZ-induced AD rats. Neurosci Lett 543:115–120. https://doi.org/10.1016/j.neulet.2013.02.065CrossRefPubMed

Liu SJ, Zhang JY, Li HL, Fang ZY, Wang Q, Deng HM, Gong CX, Grundke-Iqbal I, Iqbal K, Wang JZ (2004) Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain. J Biol Chem 279(48):50078–50088. https://doi.org/10.1074/jbc.M406109200CrossRefPubMed

Lombardo S, Maskos U (2015) Role of the nicotinic acetylcholine receptor in Alzheimer’s disease pathology and treatment. Neuropharmacology 96:255–262. https://doi.org/10.1016/j.neuropharm.2014.11.018CrossRefPubMed

Manuel Gomez Saez J (2012) Possible usefulness of growth hormone/insulin-like growth factor-I axis in Alzheimer’s disease treatment. Endocr Metab Immune Disord Drug Targets 12(3):274–286. https://doi.org/10.2174/187153012802002857CrossRef

Martín-Montañez E, Millon C, Boraldi F, Garcia-Guirado F, Pedraza C, Lara E, Santin LJ, Pavia J, Garcia-Fernandez M (2017) IGF-II promotes neuroprotection and neuroplasticity recovery in a long-lasting model of oxidative damage induced by glucocorticoids. Redox Biol 13:69–81. https://doi.org/10.1016/j.redox.2017.05.012CrossRefPubMedCentralPubMed

Marwarha G, Dasari B, Prabhakara JP, Schommer J, Ghribi O (2010) β-Amyloid regulates leptin expression and tau phosphorylation through the mTORC1 signaling pathway. J Neurochem 115(2):373–384. https://doi.org/10.1111/j.1471-4159.2010.06929.xCrossRefPubMedCentralPubMed

Marwarha G, Prasanthi JR, Schommer J, Dasari B, Ghribi O (2011) Molecular interplay between leptin, insulin-like growth factor-1, and β-amyloid in organotypic slices from rabbit hippocampus. Mol Neurodegener 6:1–8. https://doi.org/10.1186/1750-1326-6-41CrossRef

Mellott TJ, Pender SM, Burke RM, Langley EA, Blusztajn JK (2014) IGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer’s disease model mice. PLoS ONE 9(4):e94287. https://doi.org/10.1371/journal.pone.0094287CrossRefPubMedCentralPubMed

Montivero AJ, Ghersi MS, Silvero CMJ, Artur de la Villarmois E, Catalan-Figueroa J, Herrera M, Becerra MC, Hereñú CB, Pérez MF (2021) Early IGF-1 gene therapy prevented oxidative stress and cognitive deficits induced by traumatic brain injury. Front Pharmacol 12:672392. https://doi.org/10.3389/fphar.2021.672392CrossRefPubMedCentralPubMed

Nuñez A, Zegarra-Valdivia J, Fernandez de Sevilla D, Pignatelli J, Torres Aleman I (2023) The neurobiology of insulin-like growth factor I: From neuroprotection to modulation of brain states. Mol Psychiatry 28(8):3220–3230. https://doi.org/10.1038/s41380-023-02136-6CrossRefPubMed

Ogundele OM, Ebenezer PJ, Lee CC, Francis J (2017) Stress-altered synaptic plasticity and DAMP signaling in the hippocampus-PFC axis; elucidating the significance of IGF-1/IGF-1R/CaMKIIα expression in neural changes associated with a prolonged exposure therapy. Neuroscience 353:147–165. https://doi.org/10.1016/j.neuroscience.2017.04.008CrossRefPubMed

Pan J, Yao Q, Wang Y, Chang S, Li C, Wu Y, Shen J, Yang R (2024) The role of PI3K signaling pathway in Alzheimer’s disease. Front Aging Neurosci 16:1459025. https://doi.org/10.3389/fnagi.2024.1459025CrossRefPubMedCentralPubMed

Papa S, Martino PL, Capitanio G, Gaballo A, De Rasmo D, Signorile A, Petruzzella V (2012) The oxidative phosphorylation system in mammalian mitochondria. Adv Mitochondrial Med 942:3–7. https://doi.org/10.1007/978-94-007-2869-1_1CrossRef

Pardo J, Uriarte M, Cónsole GM, Reggiani PC, Outeiro TF, Morel GR, Goya RG (2016) Insulin-like growth factor-I gene therapy increases hippocampal neurogenesis, astrocyte branching and improves spatial memory in female aging rats. Eur J Neurosci 44(4):2120–2128. https://doi.org/10.1111/ejn.13278CrossRefPubMed

Pascual‐Lucas M, Viana da Silva S, Di Scala M, Garcia‐Barroso C, González‐Aseguinolaza G, Mulle C, Alberini CM, Cuadrado‐Tejedor M, Garcia‐Osta A (2014) Insulin‐like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice. EMBO Mol Med 6(10):1246–62. https://doi.org/10.15252/emmm.201404228

Pedrós I, Petrov D, Allgaier M, Sureda F, Barroso E, Beas-Zarate C, Auladell C, Pallàs M, Vázquez-Carrera M, Casadesús G (1842) Folch J (2014) Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer’s disease. Biochim Biophys Acta 9:1556–1566. https://doi.org/10.1016/j.bbadis.2014.05.025CrossRef

Pinto-Benito D, Paradela-Leal C, Ganchala D, de Castro MP, Arévalo MÁ (2022) IGF-1 regulates astrocytic phagocytosis and inflammation through the p110¿ isoform of PI3K in a sex-specific manner. Glia 70(6):1153–1169. https://doi.org/10.1002/glia.24163CrossRefPubMedCentralPubMed

Pless A, Ware D, Saggu S, Rehman H, Morgan J, Wang Q (2023) Understanding neuropsychiatric symptoms in Alzheimer’s disease: challenges and advances in diagnosis and treatment. Front Neurosci 17:1263771. https://doi.org/10.3389/fnins.2023.1263771CrossRefPubMedCentralPubMed

Porel P, Bala K, Aran KR (2024) Exploring the role of HIF-1α on pathogenesis in Alzheimer’s disease and potential therapeutic approaches. Inflammopharmacology Oct 27:1–10. https://doi.org/10.1007/s10787-024-01585-x

Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, Reusch JE (2000) Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem 275(15):10761–10766. https://doi.org/10.1074/jbc.275.15.10761CrossRefPubMed

R. Vose L, K. Stanton P (2017) Synaptic plasticity, metaplasticity and depression. Curr Neuropharmacol 15(1):71-86. https://doi.org/10.2174/1570159X14666160202121111

Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM (2005) Insulin and insulin-like growth factor expres sion and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholine. J Alzheimers Dis 8(3):247–268. https://doi.org/10.3233/jad-2005-8304CrossRefPubMed

Sádaba MC, Martín-Estal I, Puche JE (1862) Castilla-Cortázar I (2016) Insulin-like growth factor 1 (IGF-1) therapy: Mitochondrial dysfunction and diseases. Biochim Biophys Acta 7:1267–1278. https://doi.org/10.1016/j.bbadis.2016.03.010CrossRef

Saleh N, Moutereau S, Azulay JP, Verny C, Simonin C, Tranchant C, El Hawajri N, Bachoud-Lévi AC, Maison P (2010) High insulinlike growth factor I is associated with cognitive decline in Huntington disease. Neurology 75(1):57–63. https://doi.org/10.1212/WNL.0b013e3181e62076CrossRefPubMed

Selles MC, Fortuna JT, Zappa-Villar MF, de Faria YP, Souza AS, Suemoto CK, Leite RE, Rodriguez RD, Grinberg LT, Reggiani PC, Ferreira ST (2020) Adenovirus-mediated transduction of insulin-like growth factor 1 protects hippocampal neurons from the toxicity of Aβ oligomers and prevents memory loss in an Alzheimer mouse model. Mol Neurobiol 57:1473–1483. https://doi.org/10.1007/s12035-019-01827-yCrossRefPubMed

Sevigny JJ, Ryan JM, Van Dyck CH, Peng Y, Lines CR, Nessly ML (2008) Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology 71(21):1702–1708. https://doi.org/10.1212/01.wnl.0000335163.88054.e7CrossRefPubMed

Shi L, Linville MC, Tucker EW, Sonntag WE, Brunso-Bechtold JK (2005) Differential effects of aging and insulin-like growth factor-1 on synapses in CA1 of rat hippocampus. Cereb Cortex 15(5):571–577. https://doi.org/10.1093/cercor/bhh158CrossRefPubMed

Siddiqui WA, Ahad A, Ahsan H (2015) The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update. Arch Toxicol 89:289–317. https://doi.org/10.1007/s00204-014-1448-7CrossRefPubMed

Sonntag WE, Bennett SA, Khan AS, Thornton PL, Xu X, Ingram RL, Brunso-Bechtold JK (2000) Age and insulin-like growth factor-1 modulate N-methyl-D-aspartate receptor subtype expression in rats. Brain Res Bull 51(4):331–338. https://doi.org/10.1016/S0361-9230(99)00259-2CrossRefPubMed

Sonntag WE, Ramsey M, Carter CS (2005) Growth hormone and insulin-like growth factor-1 (IGF-1) and their influence on cognitive aging. Ageing Res Rev 4(2):195–212. https://doi.org/10.1016/j.arr.2005.02.001CrossRefPubMed

Steen E, Terry BM, J. Rivera E, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de La Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease–is this type 3 diabetes?. J Alzheimer's Dis 7(1):63-80. https://doi.org/10.3233/JAD-2005-7107

Sukhanov S, Higashi Y, Shai SY, Vaughn C, Mohler J, Li Y, Song YH, Titterington J, Delafontaine P (2007) IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. ATVB 27(12):2684–2690. https://doi.org/10.1161/ATVBAHA.107.156257CrossRef

Sun Z, Wu K, Gu L, Huang L, Zhuge Q, Yang S, Wang Z (2020) IGF-1R stimulation alters microglial polarization via TLR4/NF-κB pathway after cerebral hemorrhage in mice. Brain Res Bull 164:221–234. https://doi.org/10.1016/j.brainresbull.2020.08.026CrossRefPubMed

Tan J, Evin G (2012) β-Site APP-cleaving enzyme 1 trafficking and Alzheimer’s disease pathogenesis. J Neurochem 120(6):869–880. https://doi.org/10.1111/j.1471-4159.2011.07623.xCrossRefPubMed

Teleanu DM, Niculescu AG, Lungu II, Radu CI, Vladâcenco O, Roza E, Costăchescu B, Grumezescu AM, Teleanu RI (2022) An overview of oxidative stress, neuroinflammation, and neurodegenerative diseases. Int J Mol Sci 23(11):5938. https://doi.org/10.3390/ijms23115938CrossRefPubMedCentralPubMed

Torrado J, Carrascosa C (2003) Pharmacological characteristics of parenteral IGF-I administration. Curr Pharm Biotechnol 4(2):123–140. https://doi.org/10.2174/1389201033489865CrossRefPubMed

Torres-Aleman I (2007) Targeting insulin-like growth factor-1 to treat Alzheimer’s disease. Expert Opin Ther Targets 11(12):1535–1542. https://doi.org/10.1517/14728222.11.12.1535CrossRefPubMed

Trejo JL, Piriz J, Llorens-Martin MV, Fernandez AM, Bolos M, LeRoith D, Nunez A, Torres-Aleman I (2007) Central actions of liver-derived insulin-like growth factor I underlying its pro-cognitive effects. Mol Psychiatry 12(12):1118–1128. https://doi.org/10.1038/sj.mp.4002076CrossRefPubMed

Vassar R, Kuhn PH, Haass C, Kennedy ME, Rajendran L, Wong PC, Lichtenthaler SF (2014) Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neurochem 130(1):4–28. https://doi.org/10.1111/jnc.12715CrossRefPubMedCentralPubMed

Vitiello MV, Moe KE, Merriam GR, Mazzoni G, Buchner DH, Schwartz RS (2006) Growth hormone releasing hormone improves the cognition of healthy older adults. Neurobiol Aging 27(2):318–323. https://doi.org/10.1016/j.neurobiolaging.2005.01.010CrossRefPubMed

Wang X, Wang LP, Tang H, Shan WY, Wang X, Liu D, Wu YY, Tian Q, Wang JZ, Zhu LQ (2014) Acetyl-L-carnitine rescues scopolamine-induced memory deficits by restoring insulin-like growth factor II via decreasing p53 oxidation. Neuropharmacology 76:80–87. https://doi.org/10.1016/j.neuropharm.2013.08.022CrossRefPubMed

Watanabe K, Uemura K, Asada M, Maesako M, Akiyama H, Shimohama S, Takahashi R, Kinoshita A (2015) The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer’s disease. Mol Brain 8:1–4. https://doi.org/10.1186/s13041-015-0174-2CrossRef

Westwood AJ, Beiser A, DeCarli C, Harris TB, Chen TC, He XM, Roubenoff R, Pikula A, Au R, Braverman LE, Wolf PA (2014) Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy. Neurology 82(18):1613–1619. https://doi.org/10.1212/WNL.0000000000000382CrossRefPubMedCentralPubMed

Wittfeld K, Raman MR, Conner SC, Aslam A, Teumer A, Nauck M, Hosten N, Habes M, DeCarli C, Vasan RS, Beiser AS (2022) Insulin-like growth factor, inflammation, and MRI markers of Alzheimer’s disease in predominantly middle-aged adults. J Alzheimer’s Dis 88(1):311–322. https://doi.org/10.3233/JAD-220356CrossRef

Xia L, Zhu X, Zhao Y, Yang G, Zuo X, Xie P, Chen C, Han Q (2019) Genome-wide RNA sequencing analysis reveals that IGF-2 attenuates memory decline, oxidative stress and amyloid plaques in an Alzheimer’s disease mouse model (AD) by activating the PI3K/AKT/CREB signaling pathway. Int Psychogeriatr 31(7):947–959. https://doi.org/10.1017/S1041610219000383CrossRefPubMed

Xing C, Yin Y, Chang R, Gong X, He X, Xie Z (2007) Effects of insulin-like growth factor 1 on synaptic excitability in cultured rat hippocampal neurons. Exp Neurol 205(1):222–229. https://doi.org/10.1016/j.expneurol.2007.01.029CrossRefPubMed

Yang C, Sui G, Li D, Wang L, Zhang S, Lei P, Chen Z, Wang F (2021) Exogenous IGF-1 alleviates depression-like behavior and hippocampal mitochondrial dysfunction in high-fat diet mice. Physiol Behav 229:113236. https://doi.org/10.1016/j.physbeh.2020.113236CrossRefPubMed

Zappa Villar MF, López Hanotte J, Crespo R, Pardo J, Reggiani PC (2021) Insulin-like growth factor 1 gene transfer for sporadic Alzheimer’s disease: New evidence for trophic factor mediated hippocampal neuronal and synaptic recovery-based behavior improvement. Hippocampus 31(10):1137–1153. https://doi.org/10.1002/hipo.23379CrossRefPubMed

Zhang H, Gao Y, Dai Z, Meng T, Tu S, Yan Y (2011) IGF-1 reduces BACE-1 expression in PC12 cells via activation of PI3-K/Akt and MAPK/ERK1/2 signaling pathways. Neurochem Res 36:49–57. https://doi.org/10.1007/s11064-010-0260-xCrossRefPubMed

Zhang W, Bai S, Yang J, Zhang Y, Liu Y, Nie J, Meng D, Shi R, Yao Z, Wang M, Wang H (2020) FoxO1 overexpression reduces Aβ production and tau phosphorylation in vitro. Neurosci Lett 738:135322. https://doi.org/10.1016/j.neulet.2020.135322CrossRefPubMed

Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ, Frautschy SA, Cole GM (2004) Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer’s disease intervention. J Neurosci 24(49):11120–11126. https://doi.org/10.1523/JNEUROSCI.2860-04.2004CrossRefPubMedCentralPubMed

Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22(1):246–260. https://doi.org/10.1096/fj.06-7703comCrossRefPubMed

Zhao Z, Xiang Z, Haroutunian V, Buxbaum JD, Stetka B, Pasinetti GM (2007) Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer’s disease. Neurobiol Aging 28(6):824–830. https://doi.org/10.1016/j.neurobiolaging.2006.05.001CrossRefPubMed

Title: Uncovering the intricacies of IGF-1 in Alzheimer’s disease: new insights from regulation to therapeutic targeting
Authors: Navpreet Kaur
Khadga Raj Aran
Publication date: 30-01-2025
Publisher: Springer International Publishing
Keywords: Alzheimer's Disease
Alzheimer's Disease
Insulins
Insulins
Published in: Inflammopharmacology
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-025-01641-0

Keynote series | Spotlight on menopause

Springer Medicine

Uncovering the intricacies of IGF-1 in Alzheimer’s disease: new insights from regulation to therapeutic targeting

Abstract

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Please log in to get access to this content